-
St. Jude Medical Announces FDA Approval of Trifecta Valve (STJ)
Wednesday, April 20, 2011 - 9:45am | 67St. Jude Medical, Inc. (NYSE: STJ), today announced that it has received U.S. Food and Drug Administration (FDA) approval for its Trifecta™ valve. The valve, a clinically-proven replacement for diseased, damaged or malfunctioning aortic heart valves, mimics the flow of a natural, healthy heart and...
-
Deutsche Bank Has Buy Rating On St. Jude After Earnings (STJ)
Wednesday, April 20, 2011 - 9:01am | 142Deutsche Bank has a Buy rating and a $57 price target on shares of St. Jude Medical, Inc. (NYSE: STJ) after it reported earnings. In a note to investors, Deutsche Bank writes, "DB Take: Sales were in line, but remember things should improve as the US new product launches are to ramp throughout...
-
Ligand Partner Prism Pharmaceuticals To Be Acquired By Baxter (LGND, BAX)
Wednesday, April 20, 2011 - 8:01am | 83Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner Prism Pharmaceuticals has entered into a definitive agreement to be acquired by Baxter International Inc. (NYSE: BAX). Prism Pharmaceuticals recently received FDA approval for Nexterone®, an antiarrhythmic agent which...
-
Jefferies' SYK Estimates Remain Within Guidance
Wednesday, April 20, 2011 - 7:43am | 90In a report released this morning, Jefferies said that its Stryker Corp. (NYSE: SYK) estimates remain within guidance. “The full year guidance was kept at constant currency revenue growth of 11% to 13% (+5% to 7% ex-acquisitions) and adjusted EPS of $3.65 to $3.73,” Jefferies writes. “The EPS...
-
UPDATE: Morgan Keegan Raising Price Target On Intuitive Surgical After Earnings (ISRG)
Wednesday, April 20, 2011 - 7:42am | 141Morgan Keegan has a Market Perform rating and a $345 price target on shares of Intuitive Surgical Corporation (NASDAQ: ISRG), up from $330. In a note to clients, Morgan Keegan writes, "Intuitive Surgical reported solid 1Q results with revenue and EPS just modestly exceeding our estimates....
-
J.P. Morgan Neutral On Stryker Corp (SYK)
Wednesday, April 20, 2011 - 7:38am | 174J.P. Morgan Chase & Co. has a Neutral rating and a $62 price target on shares of Stryker Corp (NYSE: SYK) after the company reported earnings. In a note to investors, J.P. Morgan writes, "Stryker reported an in line 1Q result on Tuesday night, with sales of $2,015M (+12%, 10.2%cc, 4.0% organic...
-
St. Jude Guides Q2 EPS $0.83-$0.85 (STJ)
Wednesday, April 20, 2011 - 7:33am | 17St. Jude Medical (NYSE: STJ) guides Q2 EPS $0.83-$0.85.
-
Gen-Probe Incorporated Announces FDA Clears First Nucleic Acid Amplification Test to Detect Common Sexually Transmitted Infection Trichomonas Vaginalis
Wednesday, April 20, 2011 - 7:33am | 88Gen-Probe Incorporated (NASDAQ: GPRO) announced today that the US Food and Drug Administration (FDA) has cleared for marketing its APTIMA® Trichomonas vaginalis assay on the fully automated TIGRIS® system. The APTIMA assay is the first amplified nucleic acid test specifically cleared to detect...
-
St. Jude Medical Reports Q1 EPS of $0.80 vs. $0.78; Revenues $1.38B vs. $1.38B
Wednesday, April 20, 2011 - 7:31am | 22St. Jude Medical (NYSE: STJ) Reports Q1 EPS of $0.80 vs. $0.78; Revenues $1.38B vs. $1.38B
-
Wunderlich Securities Has Hold Rating On Stryker Corporation (SYK)
Wednesday, April 20, 2011 - 7:28am | 152Wunderlich Securities has a Hold rating and a $56 price target on shares of Stryker Corporation (NYSE: SYK) after the company reported earnings. In a note to investors, Wunderlich writes, "Stryker Corp. (SYK) announced its 1Q11 results Tuesday after the close. EPS of $0.90 beat our estimate and...
-
Deutsche Bank Comments On Stryker Following Solid Earnings Report
Wednesday, April 20, 2011 - 7:12am | 216Stryker's (NYSE: SYK) 1Q sales were in line with Consensus at $2.0B, up 12% reported and 10% ex-FX. Underlying hip and knee sales were below Deutsche Bank's estimate and likely the Street. However, MedSurg made up the difference. After adjusting for acquisitions and FX, sales were up just 4%--far...
-
Morgan Keegan Raises PT On Intuitive Surgical Corporation To $345
Wednesday, April 20, 2011 - 6:19am | 29Morgan Keegan has raised the price target on Intuitive Surgical Corporation (NASDAQ: ISRG) from $330 to $345 and maintains its Market Perform rating.
-
Intuitive Surgical Beats On Top And Bottom Lines (ISRG)
Tuesday, April 19, 2011 - 5:54pm | 96Intuitive Surgical (NASDAQ: ISRG), makers of the daVinci Surgical System, released its Q1 earnings results after the closing bell, beating Wall Street estimates. The company reported net income of $104.1 million or $2.59 per share, compared to $85.3 million or $2.12 per share, in the prior year...
-
UPDATE: Intuitive Surgical Ticks Lower After Beating EPS and Revenues Estimates (ISRG)
Tuesday, April 19, 2011 - 4:15pm | 40Intuitive Surgical (NASDAQ: ISRG) ticks fractionally lower after reporting earnings today. Intuitive Surgical reported EPS of $2.59/share versus the $2.49/share estimate. The company also reported revenues of $3888.1M versus the $381M estimate.
-
Intuitive Surgical Reports EPS of $2.59 vs. $2.49 Estimate; Revenue $388.1M vs. $381.21M (ISRG)
Tuesday, April 19, 2011 - 4:05pm | 21Intuitive Surgical (NASDAQ: ISRG) Reports EPS of $2.59 vs. $2.49 Estimate; Revenue $388.1M vs. $381.21M